#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	12048	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2367	498.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1460	1460	C	743	C	630	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21908	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3539	604.8	0	.	n	.	0	T695C	SNP	695	695	T	978	978	C	857	C	777	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21908	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3539	604.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1620	1620	A	646	A	594	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21908	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3539	604.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2254	2254	C	657	C	563	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21908	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3539	604.8	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2328	2328	G	668	G	583	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21908	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3539	604.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2880	2880	C	675	C	578	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	984	folP	852	852	100.0	folP.l15.c30.ctg.1	1725	55.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1076	1078	AGC	108;111;111	A;G;C	94;97;96	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2280	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3280	67.1	1	SNP	p	S91F	0	.	.	271	273	TCC	563	565	TCC	77;78;78	T;C;C,T	69;70;68,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2280	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3280	67.1	1	SNP	p	D95N	0	.	.	283	285	GAC	575	577	GAC	83;84;82	G;A;C	76;77;75	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2280	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3280	67.1	1	SNP	p	D95G	0	.	.	283	285	GAC	575	577	GAC	83;84;82	G;A;C	76;77;75	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	710	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1392	49.1	1	SNP	p	G45D	1	.	.	133	135	GAC	652	654	GAC	112;115;114	G;A;C	95;98;98	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	532	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1080	46.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2140	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2988	69.1	1	SNP	p	D86N	0	.	.	256	258	GAC	578	580	GAC	97;97;97	G;A,G;C	93;89,1;93	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2140	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2988	69.1	1	SNP	p	S87W	0	.	.	259	261	AGT	581	583	AGT	99;100;99	A;G;T	92;95;95	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2140	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2988	69.1	1	SNP	p	S87R	0	.	.	259	261	AGT	581	583	AGT	99;100;99	A;G;T	92;95;95	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2140	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2988	69.1	1	SNP	p	S87I	0	.	.	259	261	AGT	581	583	AGT	99;100;99	A;G;T	92;95;95	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2140	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2988	69.1	1	SNP	p	S88P	0	.	.	262	264	TCC	584	586	TCC	100;98;98	T;C;C	96;94;94	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1868	parE	1986	1986	100.0	parE.l6.c17.ctg.1	2784	64.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1491	1493	GGC	55;55;55	G;G;C	50;50;50	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1222	1224	GCA	133;134;132	G;C;A	116;117;116	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1225	1227	ATC	127;128;129	A;T;C	113;114;114	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1237	1239	GTG	127;126;125	G;T;G	111;108;108	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1237	1239	GTG	127;126;125	G;T;G	111;108;108	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1741	1743	ACC	84;84;84	A;C;C	74;75;75	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1795	1797	GCG	59;60;61	G;C;G	59;60;61	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1795	1797	GCG	59;60;61	G;C;G	59;60;61	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1918	1920	GGC	72;73;72	G;G;C	64;65;65	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1927	1929	GGC	58;58;57	G;G;C	52;51;52	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2272	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2224	98.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1945	1947	CCG	40;37;37	C;C;G	40;36;36	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	3808	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	2987	123.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1082	porA	1146	1146	99.83	porA.l15.c30.ctg.1	1941	54.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	580	580	C	51	C	47	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	A26V	NONSYN	76	78	GCC	306	308	GTC	91;91;90	G;T;C	86;85;84	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	E48G	NONSYN	142	144	GAA	372	374	GGA	123;124;132	G;G;A	97;98;101	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	T87A	NONSYN	259	261	ACT	489	491	GCT	98;97;97	G;C;T	86;85;86	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	495	497	AGC	96;96;91	A;G;C	85;85;80	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	.	MULTIPLE	358	359	AA	587	588	CG	48;47	C;G	42;41	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	.	MULTIPLE	361	362	GA	590	592	CAG	45;44;45	C;A;G	40;40;41	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	N122K	NONSYN	364	366	AAC	594	596	AAA	46;49;49	A;A;A	42;45;45	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	A125T	NONSYN	373	375	GCT	603	605	ACT	57;60;59	A;C;T	53;56;55	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	N134S	NONSYN	400	402	AAT	630	632	AGT	61;62;67	A;G;T	55;55;58	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	E137K	NONSYN	409	411	GAA	639	641	AAA	66;66;66	A;A;A	60;60;60	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	K143E	NONSYN	427	429	AAA	657	659	GAA	74;75;75	G;A;A	64;65;65	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	681	683	GCA	95;95;95	G;C;A	80;80;80	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	789	791	CAA	173;173;175	C;A;A	136;136;138	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	N189S	NONSYN	565	567	AAC	795	797	AGC	178;178;178	A;G;C	137;137;138	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	M209I	NONSYN	625	627	ATG	855	857	ATC	147;147;147	A;T;C	120;119;120	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	0	.	p	.	0	E210fs	FSHIFT	628	628	G	858	858	G	144	G	119	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	1	SNP	p	G120K	1	.	.	358	360	AAG	587	589	CGG	48;47;46	C;G;G	42;41;41	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	1	SNP	p	A121D	1	.	.	361	363	GAC	590	593	CGC	45;45;46	C;G;C	40;41;42	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1320	porB1b	1041	1041	96.56	porB1b.l6.c4.ctg.1	1514	84.9	1	SNP	p	D121N	0	.	.	361	363	GAC	590	593	CGC	45;45;46	C;G;C	40;41;42	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	5278	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	4828	106.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1981	1983	AAT	112;112;113	A;A;T	102;102;103	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	456	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1046	42.7	1	SNP	p	V57M	1	.	.	169	171	ATG	558	560	ATG	91;92;96	A;T;G	77;80;84	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
